Oxford BioMedica plc’s (OXB) “Buy” Rating Reaffirmed at Jefferies Group LLC
Jefferies Group LLC reissued their buy rating on shares of Oxford BioMedica plc (LON:OXB) in a report published on Friday. They currently have a GBX 8 ($0.10) target price on the biopharmaceutical company’s stock.
Separately, N+1 Singer reissued a hold rating and set a GBX 3.30 ($0.04) price objective on shares of Oxford BioMedica plc in a research note on Thursday.
Oxford BioMedica plc (LON:OXB) traded down 0.36% during midday trading on Friday, reaching GBX 5.50. The company’s stock had a trading volume of 6,338,186 shares. The stock’s 50-day moving average price is GBX 4.38 and its 200-day moving average price is GBX 3.89. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 6.86. The firm’s market capitalization is GBX 146.57 million.
Your IP Address:
In related news, insider Lorenzo Tallarigo acquired 67,165 shares of Oxford BioMedica plc stock in a transaction dated Friday, February 24th. The stock was acquired at an average cost of GBX 4 ($0.05) per share, with a total value of £2,686.60 ($3,318.02).
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with Analyst Ratings Network's FREE daily email newsletter.